Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.39Last Year’s EPS
-0.39Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -29.61%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong international growth and successful product initiatives but was balanced by moderated U.S. growth, increased operating expenses, and a slight decline in gross margin. The DOJ investigation closure is a positive note, but the financial challenges, including net loss, present concerns.Company Guidance
During the Pulmonx First Quarter 2025 Earnings Conference Call, guidance emphasized maintaining the previously communicated revenue target of $96 million to $98 million for the full year 2025, reflecting anticipated growth of 16% to 18% on a constant currency basis. The company reported $22.5 million in sales for Q1, representing a 20% increase year-over-year. The guidance also highlighted a gross margin expectation of approximately 74% for the year and projected operating expenses in the range of $133 million to $135 million, including $22 million in non-cash stock-based compensation. Pulmonx expects U.S. growth to accelerate in the second half of the year, driven by various initiatives such as the LungTraX Detect system and expanded physician and patient education efforts. Internationally, Pulmonx anticipates continued robust growth, particularly in China, which contributed significantly to the 39% year-over-year increase in international revenue during the first quarter.Strong Revenue Growth
Pulmonx reported worldwide sales of $22.5 million in Q1 2025, representing 20% growth over the same period last year and 21% on a constant currency basis.
International Revenue Surge
International revenue increased by 39% from $6 million last year to $8.3 million in Q1 2025, with a 43% increase on a constant currency basis, driven by strong demand in China.
Commercial and Product Initiatives
Introduction of LungTraX Detect is seeing positive momentum, with dozens of accounts in various contracting phases. Successful peer-to-peer education and community physician engagement efforts are underway.
DOJ Investigation Closure
The DOJ formally declined to intervene in the case filed under the False Claims Act and the Anti-Kickback Statute, allowing the company to focus on delivering value to stakeholders.
LUNG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LUNG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $4.83 | $3.77 | -21.95% |
Feb 19, 2025 | $6.64 | $8.78 | +32.23% |
Oct 30, 2024 | $6.79 | $6.25 | -7.95% |
Jul 31, 2024 | $6.91 | $6.49 | -6.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pulmonx (LUNG) report earnings?
Pulmonx (LUNG) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Pulmonx (LUNG) earnings time?
Pulmonx (LUNG) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LUNG EPS forecast?
LUNG EPS forecast for the fiscal quarter 2025 (Q2) is -0.39.